Extended Data Table 1.

Summary of COVID-19 severity after COVID-19 vaccination split by serological response

Summary of COVID-19 severity reported in combined follow-up periods after COVID-19 vaccination for all immunocompromised patients in OCTAVE, split by disease subgroup and based on Roche anti-RBD Ig assay result ≥0.8 AU ml⁻¹, low response <380 AU ml⁻¹ and high response >380 AU mL⁻¹ at the post-V2 timepoint.

^# % of total OCTAVE infections.